Coloplast A/S

CPSE:COLO B Stock Report

Market Cap: DKK 99.2b

Coloplast Valuation

Is COLO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: COLO B (DKK440.4) is trading below our estimate of future cash flow value (DKK937.75)

Significantly Below Future Cash Flow Value: COLO B is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLO B?

Key metric: As COLO B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLO B. This is calculated by dividing COLO B's market cap by their current earnings.
What is COLO B's PE Ratio?
PE Ratio47.1x
EarningsDKK 2.11b
Market CapDKK 99.16b

Price to Earnings Ratio vs Peers

How does COLO B's PE Ratio compare to its peers?

The above table shows the PE ratio for COLO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.7x
DEMANT Demant
25.3x12.41%DKK 59.9b
AMBU B Ambu
40.9x23.75%DKK 19.5b
EMBLA Embla Medical hf
20.9x12.82%DKK 12.7b
COO Cooper Companies
63.5x28.05%US$14.9b
COLO B Coloplast
47.1x26.74%DKK 99.2b

Price-To-Earnings vs Peers: COLO B is expensive based on its Price-To-Earnings Ratio (47.1x) compared to the peer average (37.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does COLO B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
COLO B 47.1xIndustry Avg. 27.0xNo. of Companies11PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COLO B is expensive based on its Price-To-Earnings Ratio (47.1x) compared to the European Medical Equipment industry average (26.5x).

Price to Earnings Ratio vs Fair Ratio

What is COLO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLO B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47.1x
Fair PE Ratio38.9x

Price-To-Earnings vs Fair Ratio: COLO B is expensive based on its Price-To-Earnings Ratio (47.1x) compared to the estimated Fair Price-To-Earnings Ratio (38.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLO B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 440.40
DKK 462.29
+4.97%
13.06%DKK 600.00DKK 345.00n/a21
Aug ’27DKK 429.40
DKK 458.24
+6.72%
13.74%DKK 600.00DKK 345.00n/a21
Jul ’27DKK 378.70
DKK 458.48
+21.07%
13.75%DKK 600.00DKK 345.00n/a21
Jun ’27DKK 382.00
DKK 461.90
+20.92%
12.68%DKK 600.00DKK 380.00n/a21
May ’27DKK 402.80
DKK 500.15
+24.17%
17.87%DKK 760.00DKK 380.00n/a20
Apr ’27DKK 442.80
DKK 566.68
+27.98%
14.33%DKK 760.00DKK 400.00n/a19
Mar ’27DKK 488.00
DKK 588.44
+20.58%
12.21%DKK 760.00DKK 470.00n/a18
Feb ’27DKK 536.00
DKK 655.61
+22.32%
9.96%DKK 800.00DKK 541.00n/a18
Jan ’27DKK 546.40
DKK 689.06
+26.11%
12.96%DKK 962.00DKK 541.00n/a18
Dec ’26DKK 589.20
DKK 688.67
+16.88%
13.06%DKK 962.00DKK 535.00n/a18
Nov ’26DKK 585.60
DKK 686.00
+17.14%
13.59%DKK 962.00DKK 520.00n/a18
Oct ’26DKK 557.60
DKK 706.50
+26.70%
12.26%DKK 962.00DKK 585.00n/a18
Sep ’26DKK 623.80
DKK 718.06
+15.11%
11.86%DKK 962.00DKK 585.00n/a18
Aug ’26DKK 593.40
DKK 743.79
+25.34%
11.04%DKK 962.00DKK 600.00DKK 429.4019
Jul ’26DKK 599.40
DKK 749.05
+24.97%
10.99%DKK 962.00DKK 600.00DKK 378.7019
Jun ’26DKK 635.60
DKK 756.85
+19.08%
10.86%DKK 962.00DKK 640.00DKK 382.0020
May ’26DKK 705.40
DKK 896.20
+27.05%
11.46%DKK 1,050.00DKK 694.00DKK 402.8020
Apr ’26DKK 726.40
DKK 910.71
+25.37%
10.85%DKK 1,050.00DKK 700.00DKK 442.8021
Mar ’26DKK 764.00
DKK 909.76
+19.08%
10.85%DKK 1,050.00DKK 700.00DKK 488.0021
Feb ’26DKK 830.00
DKK 911.43
+9.81%
10.74%DKK 1,030.00DKK 700.00DKK 536.0021
Jan ’26DKK 786.20
DKK 924.43
+17.58%
9.41%DKK 1,030.00DKK 700.00DKK 546.4021
Dec ’25DKK 889.40
DKK 924.67
+3.97%
9.44%DKK 1,030.00DKK 700.00DKK 589.2021
Nov ’25DKK 871.80
DKK 913.33
+4.76%
11.03%DKK 1,050.00DKK 700.00DKK 585.6021
Oct ’25DKK 876.40
DKK 913.60
+4.24%
11.03%DKK 1,060.00DKK 700.00DKK 557.6020
Sep ’25DKK 920.20
DKK 911.35
-0.96%
11.26%DKK 1,060.00DKK 700.00DKK 623.8020
Aug ’25DKK 896.00
DKK 905.90
+1.10%
10.97%DKK 1,060.00DKK 710.00DKK 593.4020
DKK 462.29
Fair Value
4.7% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/11 00:38
End of Day Share Price 2026/08/11 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coloplast A/S is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Robert BateBarclays